Please provide the following information relating to NSCLC patients treated by your Trust in the 3 months, July 2018 to September 2018 inclusive.
If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below.
1. Total number treated Stage IIIB/IV NSCLC Patients
Patients with NSCLC Stage IIIB/IV (Stage 3b/4)
Total number NSCLC patients
Other (please specify)
Data not held/accessible
Of the Stage IIIB/IV NSCLC patients, please indicate the number of patients treated by your Trust in the 3 months July 2018 to September 2018 inclusive, with the following therapies.
2. Total number treated Stage IIIB/IV NSCLC Patients. If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:
Docetaxel (mono or combination therapy)
3. If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust(s) patients are referred: